REXAHN PHARMACEUTICALS

rexahn-pharmaceuticals-logo

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for cancer, central nervous system (CNS) disorders, sexual dysfunction, and other unmet medical needs in the United States. Its drug candidates in Phase II clinical trials include Archexin, the lead anticancer drug candidate is an inhibitor of the protein kinase Akt for the treatment of pancreatic cancer and renal cell carcinoma; Serdaxin for the tr... eatment of depression and neurodegenerative disorders; and Zoraxel, a drug for sexual dysfunction that modulates the sexual activity control center in the brain. Its pre-clinical pipeline products include RX-1792, a molecule targeted anticancer drug candidate; RX-5902, a molecule microtubule inhibitor anticancer drug candidate; RX-3117, a molecule anti-metabolite nucleoside anticancer drug candidate; RX-8243, a molecule aurora kinase inhibitor anticancer drug candidate; RX-0201-Nano, nanoliposomal anticancer Akt-1 inhibitor; RX-0047-Nano, nanoliposomal anticancer HIF-1 alpha inhibitor; and RX-21101 & RX-21202, a nano-polymer anticancer. The company has various collaborative research and development relationships with universities, research institutions, and other organizations, including Teva Pharmaceutical Industries; TheraTarget, Inc.; Korea Research Institute of Chemical Technology; The University of Maryland Baltimore; and Revaax Pharmaceuticals LLC. Rexahn Pharmaceuticals, Inc. is based in Rockville, Maryland.

#SimilarOrganizations #People #Website #More

REXAHN PHARMACEUTICALS

Industry:
Biotechnology Medical Device Pharmaceutical

Founded:
2001-01-01

Address:
Rockville, Maryland, United States

Country:
United States

Website Url:
http://www.rexahn.com

Total Employee:
11+

Status:
Active

Contact:
2402685310

Email Addresses:
info@rexahn.com

Total Funding:
5 M USD

Technology used in webpage:
SPF Microsoft Exchange Online Amazon Office 365 Mail Microsoft Azure DNS COVID-19 Amazon Virginia Region IIS 10 Network Solutions DNS GlobalSign Domain Verification


Similar Organizations

adamas-pharmaceuticals-logo

Adamas Pharmaceuticals

Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.

apellis-pharmaceuticals-logo

Apellis Pharmaceuticals

Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.

reata-pharmaceuticals-logo

Reata Pharmaceuticals

Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.

sirnaomics-logo

Sirnaomics

Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.

Current Employees Featured

rick-soni_image

Rick Soni
Rick Soni President and COO @ Rexahn Pharmaceuticals
President and COO

not_available_image

Chang H. Ahn
Chang H. Ahn CEO — Founder and Chairman @ Rexahn Pharmaceuticals
CEO — Founder and Chairman

Founder


not_available_image

Chang H. Ahn

Stock Details


Company's stock symbol is NASDAQ:REXN

Official Site Inspections

http://www.rexahn.com

Unable to get host informations!!!

Rexahn.com lookup results from whois.networksolutions.com server:
  • Domain created: 18th-Jan-2001
  • Domain updated: 17th-Jan-2025
  • Domain expires: 18th-Jan-2026 1 Year, 0 Days left
  • Website age: 23 Years, 365 Days
  • Registrar Domain ID: 52454307_DOMAIN_COM-VRSN
  • Registrar Url: http://networksolutions.com
  • Registrar WHOIS Server: whois.networksolutions.com
  • Registrar Abuse Contact Email: domain.operations@web.com
  • Registrar Abuse Contact Phone: +1.8777228662

More informations about "Rexahn Pharmaceuticals"

Rexahn Pharmaceuticals - Crunchbase Company Profile & Funding

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for cancer, central nervous …See details»

Opus Genetics - Home

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing important new therapies for the treatment of inherited retinal diseases (IRDs) and other retinal and refractive disorders. Targeting mutations in genes …See details»

Rexahn Pharmaceuticals - LinkedIn

Rexahn Pharmaceuticals Inc. (NYSE American:RNN) is a clinical stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of cancer.See details»

Rexahn Pharmaceuticals - PitchBook

Rexahn Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is dedicated to the discovery, development, and commercialization of treatments for cancer.See details»

Rexahn Pharmaceuticals, Inc. - AnnualReports.com

Rexahn Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 11-3516358 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer …See details»

Rexahn and Ocuphire Enter into Definitive Merger Agreement

Jun 18, 2020 · Transaction to Create a Nasdaq-listed Biopharmaceutical Company Focused on Advancing Ocuphire’s Late-Stage Clinical Pipeline of Ophthalmic Drug Candidates. $21.15 …See details»

Rexahn Pharmaceuticals - Products, Competitors, Financials, …

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing targeted therapeutics for cancer treatment. The company's main offerings include novel …See details»

Ocuphire Pharma Completes Transactions and Begins Trading

Nov 6, 2020 · Merger completed with Rexahn Pharmaceuticals creating a Nasdaq-listed Biopharmaceutical Company Focused on Advancing Ocuphire’s Late-Stage Clinical Pipeline …See details»

Rexahn Pharma up big on announced merger with Ocuphire Pharma

Jun 18, 2020 · Rexahn Pharmaceuticals (NASDAQ: REXN) has agreed to merge with privately held Ocuphire Pharma, a developer therapies for eye disorders, in an all-stock deal. The …See details»

Rexahn Pharmaceuticals Announces Stockholder Approval of All …

Nov 2, 2020 · Rexahn Pharmaceuticals, Inc. (NasdaqCM: REXN) is a biotechnology company that has been focused on the development of innovative therapies to improve patient outcomes in …See details»

Rexahn to Explore Strategic Alternatives - Ocuphire Pharma, Inc.

Rexahn Pharmaceuticals Inc. (NasdaqCM: REXN) is a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat.See details»

Rexahn Pharmaceuticals - Contacts, Employees, Board Members, …

Rexahn Pharmaceuticals has 2 current employee profiles, including President and COO Rick Soni. Rexahn Pharmaceuticals develops treatments for cancer, central nervous system …See details»

Rexahn and Ocuphire Enter into Definitive Merger Agreement

Jun 18, 2020 · Transaction to Create a Nasdaq-listed Biopharmaceutical Company Focused on Advancing Ocuphire’s Late-Stage Clinical Pipeline of Ophthalmic Drug Candidates. $21.15 …See details»

Rexahn Pharmaceuticals Announces Expected Effectiveness of

ROCKVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN) (“Rexahn”) announced today that the merger transaction between Rexahn …See details»

Rexahn Pharmaceuticals Announces Expected Effectiveness of …

ROCKVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that the merger transaction between Rexahn …See details»

Rexahn Pharmaceuticals | REXN Stock Price, Company Overview

Leading the group were shares of Alnylam Pharmaceuticals (ALNY), up about 52.9% and shares of Rexahn Pharmaceuticals (RNN) up about 37.7% on the day.See details»

Rexahn Pharmaceuticals Announces Stockholder Approval of

Nov 2, 2020 · Rexahn Pharmaceuticals, Inc. (NasdaqCM: REXN) is a biotechnology company that has been focused on the development of innovative therapies to improve patient outcomes in …See details»

Rexahn Pharmaceuticals Announces Presentations at the American …

Rexahn Pharmaceuticals Inc. (NYSE American:RNN) is a clinical stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of cancer.See details»

Rexahn and Ocuphire Enter into Definitive Merger Agreement

Jun 18, 2020 · Transaction to Create a Nasdaq-listed Biopharmaceutical Company Focused on Advancing Ocuphire’s Late-Stage Clinical Pipeline of Ophthalmic Drug Candidates. $21.15 …See details»

Rexahn Pharmaceuticals Inc (REXN) Stock Message Board

Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) is a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are …See details»

linkstock.net © 2022. All rights reserved